{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood samples were planned to be collected at indicated time points for pharmacokinetic analysis of 5-Azacitidine.","groups":[{"description":"Participants were planned to receive GSK3326595 in combination with 5-Azacitidine in dose escalation cohort during Part 2 of the study.","id":"OG000","title":"Part 2-Dose Escalation: GSK3326595+5-Azacitidine"},{"description":"Participants were planned to receive GSK3326595 in combination with 5-Azacitidine in dose expansion cohort during Part 2 of the study.","id":"OG001","title":"Part 2-Dose Expansion: GSK3326595+5-Azacitidine"}],"populationDescription":"PK Population. Data was not collected as no participants were enrolled in Part 2.","reportingStatus":"POSTED","timeFrame":"Days 1 and 8:Pre-dose(within 1 hour prior to dosing),5minute(+/-2minute),30minute(+/-5minute),1hour(+/-5minute),2hours(+/-5minute),3hours(+/-5minute),4hours(+/-10minute),6hours(+/-10minute),8hours(+/-15minute) post-dose","title":"Part 2: Time Invariance Following Administration of 5-Azacitidine","type":"SECONDARY"}